Journal articleJ Clin Oncol2026
Axitinib and Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors: A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial (AXINET, GETNE 1107).
- Journal
- J Clin Oncol
- Published
- 20 February 2026
- Citations
- 4
- License
- cc by-nc-nd
These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Trials 1
- Its registry lists this paper as resultsSandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas NCT01744249↗
The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.